{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:50:28Z","timestamp":1790877028526,"version":"4.1.0"},"reference-count":72,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T00:00:00Z","timestamp":1677801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Food and Drug Administration","award":["U01FD007064"],"award-info":[{"award-number":["U01FD007064"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In 2020, the ongoing US opioid overdose crisis collided with the emerging COVID-19 pandemic. Opioid overdose deaths (OODs) rose an unprecedented 38%, due to a combination of COVID-19 disrupting services essential to people who use drugs, continued increases in fentanyls in the illicit drug supply, and other factors. How much did these factors contribute to increased OODs? We used a validated simulation model of the opioid overdose crisis, SOURCE, to estimate excess OODs in 2020 and the distribution of that excess attributable to various factors. Factors affecting OODs that could have been disrupted by COVID-19, and for which data were available, included opioid prescribing, naloxone distribution, and receipt of medications for opioid use disorder. We also accounted for fentanyls\u2019 presence in the heroin supply. We estimated a total of 18,276 potential excess OODs, including 1,792 lives saved due to increases in buprenorphine receipt and naloxone distribution and decreases in opioid prescribing. Critically, growth in fentanyls drove 43% (7,879) of the excess OODs. A further 8% is attributable to first-ever declines in methadone maintenance treatment and extended-released injectable naltrexone treatment, most likely due to COVID-19-related disruptions. In all, 49% of potential excess OODs remain unexplained, at least some of which are likely due to additional COVID-19-related disruptions. While the confluence of various COVID-19-related factors could have been responsible for more than half of excess OODs, fentanyls continued to play a singular role in excess OODs, highlighting the urgency of mitigating their effects on overdoses.<\/jats:p>","DOI":"10.1093\/pnasnexus\/pgad064","type":"journal-article","created":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T12:24:05Z","timestamp":1677932645000},"source":"Crossref","is-referenced-by-count":9,"title":["Enumerating contributions of fentanyls and other factors to the unprecedented 2020 rise in opioid overdose deaths: model-based analysis"],"prefix":"10.1093","volume":"2","author":[{"given":"Erin J","family":"Stringfellow","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital, Harvard Medical School , 101 Merrimac St, Boston, MA 02114 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5084-0911","authenticated-orcid":false,"given":"Tse Yang","family":"Lim","sequence":"additional","affiliation":[{"name":"Harvard T.H. Chan School of Public Health , 677 Huntington Ave, Boston, MA 02115 , USA"},{"name":"MIT Sloan School of Management , 100 Main St, Cambridge, MA 02142 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"DiGennaro","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Harvard Medical School , 101 Merrimac St, Boston, MA 02114 , USA"},{"name":"MIT Sloan School of Management , 100 Main St, Cambridge, MA 02142 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8973-6916","authenticated-orcid":false,"given":"Zeynep","family":"Hasgul","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Harvard Medical School , 101 Merrimac St, Boston, MA 02114 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6769-2732","authenticated-orcid":false,"given":"Mohammad S","family":"Jalali","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Harvard Medical School , 101 Merrimac St, Boston, MA 02114 , USA"},{"name":"MIT Sloan School of Management , 100 Main St, Cambridge, MA 02142 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,3]]},"reference":[{"key":"2023072815182081000_pgad064-B1","author":"Ahmad","year":"2022"},{"key":"2023072815182081000_pgad064-B2","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.2105\/AJPH.2021.306256","article-title":"COVID-19 and the drug overdose crisis: uncovering the deadliest months in the United States, January\u2013July 2020","volume":"111","author":"Friedman","year":"2021","journal-title":"Am J Public Health"},{"key":"2023072815182081000_pgad064-B3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.15585\/mmwr.mm6802a4","article-title":"Notes from the field: fentanyl drug submissions\u2014United States, 2010\u20132017","volume":"68","author":"Springer","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023072815182081000_pgad064-B4","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.15585\/mmwr.mm6643e1","article-title":"Deaths involving fentanyl, fentanyl analogs, and U-47700\u201310 states, July-December 2016","volume":"66","author":"O\u2019Donnell","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023072815182081000_pgad064-B5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13011-021-00423-5","article-title":"The impact of the novel coronavirus disease (COVID-19) pandemic on drug overdose-related deaths in the United States and Canada: a systematic review of observational studies and analysis of public health surveillance data","volume":"16","author":"Imtiaz","year":"2021","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"2023072815182081000_pgad064-B6","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1080\/07853890.2022.2067350","article-title":"Opioid overdose decedent characteristics during COVID-19","volume":"54","author":"Garcia","year":"2022","journal-title":"Ann Med"},{"key":"2023072815182081000_pgad064-B7","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108314","article-title":"Steep increases in fentanyl-related mortality west of the Mississippi River: recent evidence from county and state surveillance","volume":"216","author":"Shover","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"2023072815182081000_pgad064-B8","doi-asserted-by":"crossref","first-page":"202","DOI":"10.15585\/mmwr.mm7006a4","article-title":"Trends and geographic patterns in drug and synthetic opioid overdose deaths\u2014United States, 2013\u20132019","volume":"70","author":"Mattson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023072815182081000_pgad064-B9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12954-022-00653-1","article-title":"Impact of COVID-19 among people who use drugs: a qualitative study with harm reduction workers and people who use drugs","volume":"19","author":"Conway","year":"2022","journal-title":"Harm Reduct J"},{"key":"2023072815182081000_pgad064-B10","doi-asserted-by":"crossref","first-page":"9751","DOI":"10.3390\/ijerph19159751","article-title":"A qualitative exploration of the functional, social, and emotional impacts of the COVID-19 pandemic on people who use drugs","volume":"19","author":"Kelly","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"2023072815182081000_pgad064-B11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12954-021-00568-3","article-title":"The impact of COVID-19 on people who inject drugs in New York city: increased risk and decreased access to services","volume":"18","author":"Aponte-Melendez","year":"2021","journal-title":"Harm Reduct J"},{"key":"2023072815182081000_pgad064-B12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13722-022-00303-8","article-title":"Structural and community changes during COVID-19 and their effects on overdose precursors among rural people who use drugs: a mixed-methods analysis","volume":"17","author":"Walters","year":"2022","journal-title":"Addict Sci Clin Pract"},{"key":"2023072815182081000_pgad064-B13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10461-021-03332-7","article-title":"Program adaptations to provide harm reduction services during the COVID-19 pandemic: a qualitative study of syringe services programs in the U.S","volume":"26","author":"Frost","year":"2022","journal-title":"AIDS Behav"},{"key":"2023072815182081000_pgad064-B14","author":"Addiction Policy Forum","year":"2020"},{"key":"2023072815182081000_pgad064-B15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108655","article-title":"\u201cNo home to take methadone to\u201d: experiences with addiction services during the COVID-19 pandemic among survivors of opioid overdose in Boston","volume":"135","author":"Harris","year":"2022","journal-title":"J Subst Abuse Treat"},{"key":"2023072815182081000_pgad064-B16","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/ADM.0000000000000770","article-title":"The impacts of COVID-19 on mental health, substance use, and overdose concerns of people who use drugs in rural communities","volume":"15","author":"Stack","year":"2021","journal-title":"J Addict Med"},{"key":"2023072815182081000_pgad064-B17","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109544","article-title":"Factors associated with self-reported avoidance of harm reduction services during the COVID-19 pandemic by people who use drugs in five cities in the United States and Canada","volume":"241","author":"Feder","year":"2022","journal-title":"Drug Alcohol Depend"},{"key":"2023072815182081000_pgad064-B18","doi-asserted-by":"crossref","DOI":"10.1016\/j.addbeh.2020.106754","article-title":"Substance use and abuse, COVID-19-related distress, and disregard for social distancing: a network analysis","volume":"114","author":"Taylor","year":"2021","journal-title":"Addict Behav."},{"key":"2023072815182081000_pgad064-B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12954-022-00710-9","article-title":"Attitudes toward harm reduction and low-threshold healthcare during the COVID-19 pandemic: qualitative interviews with people who use drugs in rural southern Illinois","volume":"19","author":"Rains","year":"2022","journal-title":"Harm Reduct J"},{"key":"2023072815182081000_pgad064-B20","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.3390\/ijerph19042230","article-title":"The impact of the COVID-19 pandemic on drug use behaviors, fentanyl exposure, and harm reduction service support among people who use drugs in rural settings","volume":"19","author":"Bolinski","year":"2022","journal-title":"Int J Environ Res Public Health."},{"key":"2023072815182081000_pgad064-B21","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2115714119","article-title":"Modeling the evolution of the US opioid crisis for national policy development","volume":"119","author":"Lim","year":"2022","journal-title":"Proc Natl Acad Sci USA."},{"key":"2023072815182081000_pgad064-B22","doi-asserted-by":"crossref","first-page":"8147","DOI":"10.1126\/sciadv.abm8147","article-title":"Reducing opioid use disorder and overdose deaths in the United States: a dynamic modeling analysis","volume":"8","author":"Stringfellow","year":"2022","journal-title":"Sci Adv"},{"key":"2023072815182081000_pgad064-B23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhealeco.2019.102286","article-title":"How increasing medical access to opioids contributes to the opioid epidemic: evidence from medicare part D","volume":"71","author":"Powell","year":"2020","journal-title":"J Health Econ"},{"key":"2023072815182081000_pgad064-B24","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1038\/s41380-018-0094-5","article-title":"Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis","volume":"24","author":"Ma","year":"2019","journal-title":"Mol Psychiatry"},{"key":"2023072815182081000_pgad064-B25","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/jamainternmed.2019.0272","article-title":"Association between state laws facilitating pharmacy distribution of naloxone and risk of fatal overdose","volume":"179","author":"Abouk","year":"2019","journal-title":"JAMA Intern Med"},{"key":"2023072815182081000_pgad064-B26","author":"National Center for Health Statistics"},{"key":"2023072815182081000_pgad064-B27","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1111\/add.14144","article-title":"Corrected US opioid-involved drug poisoning deaths and mortality rates, 1999\u20132015","volume":"113","author":"Ruhm","year":"2018","journal-title":"Addiction"},{"key":"2023072815182081000_pgad064-B28","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1007\/s10461-020-02886-2","article-title":"The impact of COVID-19 on syringe services programs in the United States","volume":"24","author":"Glick","year":"2020","journal-title":"AIDS Behav"},{"key":"2023072815182081000_pgad064-B29","article-title":"With meetings banned, millions struggle to stay sober on their own","author":"Hoffman","year":"2020","journal-title":"New York Times"},{"key":"2023072815182081000_pgad064-B30","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2021.3833","article-title":"Assessment of state and federal health policies for opioid use disorder treatment during the COVID-19 pandemic and beyond","volume":"2","author":"Pessar","year":"2021","journal-title":"JAMA Health Forum"},{"key":"2023072815182081000_pgad064-B31","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2022.0093","article-title":"Trends in engagement with opioid use disorder treatment among medicaid beneficiaries during the COVID-19 pandemic","volume":"3","author":"Tilhou","year":"2022","journal-title":"JAMA Health Forum"},{"key":"2023072815182081000_pgad064-B32","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1001\/jama.2020.22154","article-title":"Changes in outpatient buprenorphine dispensing during the COVID-19 pandemic","volume":"324","author":"Cance","year":"2020","journal-title":"JAMA"},{"key":"2023072815182081000_pgad064-B33","author":"U.S. Department of Justice Drug Enforcement Administration","year":"2021"},{"key":"2023072815182081000_pgad064-B34","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/add.15222","article-title":"The dawn of a new synthetic opioid era: the need for innovative interventions","volume":"116","author":"Pardo","year":"2021","journal-title":"Addiction"},{"key":"2023072815182081000_pgad064-B35","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102976","article-title":"Consumer protection in drug policy: the human rights case for safe supply as an element of harm reduction","volume":"91","author":"Csete","year":"2021","journal-title":"Int J Drug Policy"},{"key":"2023072815182081000_pgad064-B36","article-title":"Fentanyl from the government? A Vancouver experiment aims to stop overdoses","author":"Nolen","year":"2022","journal-title":"New York Times"},{"key":"2023072815182081000_pgad064-B37","author":"Smart","year":"2018"},{"key":"2023072815182081000_pgad064-B38","author":"Pardo","year":"2019"},{"key":"2023072815182081000_pgad064-B39","author":"Miller","year":"2022"},{"key":"2023072815182081000_pgad064-B40","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1080\/00952990.2022.2097917","article-title":"Addressing stimulant use disorder through state opioid response grants from the substance abuse and mental health services administration: Missouri\u2019s initial approach","volume":"48","author":"Winograd","year":"2022","journal-title":"Am J Drug Alcohol Abuse"},{"key":"2023072815182081000_pgad064-B41","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102661","article-title":"An assessment of the limits of detection, sensitivity and specificity of three devices for public health-based drug checking of fentanyl in street-acquired samples","volume":"77","author":"Green","year":"2020","journal-title":"Int J Drug Policy"},{"key":"2023072815182081000_pgad064-B42","article-title":"Governor Newsom vetoes bill for safe drug-injection sites in California","author":"Cowan","year":"2022","journal-title":"New York Times"},{"key":"2023072815182081000_pgad064-B43","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1080\/10826084.2021.1901934","article-title":"The early impact of social distancing measures on drug use","volume":"56","author":"Christie","year":"2021","journal-title":"Subst Use Misuse"},{"key":"2023072815182081000_pgad064-B44","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13104-021-05601-z","article-title":"Opioid use, motivation to quit, and treatment status related to COVID-19: a cross-sectional study","volume":"14","author":"Parker","year":"2021","journal-title":"BMC Res Notes"},{"key":"2023072815182081000_pgad064-B45","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103237","article-title":"Changes in substance supply and use characteristics among people who use drugs (PWUD) during the COVID-19 global pandemic: a national qualitative assessment in Canada","volume":"93","author":"Ali","year":"2021","journal-title":"Int J Drug Policy"},{"key":"2023072815182081000_pgad064-B46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0255396","article-title":"Experiences of people with opioid use disorder during the COVID-19 pandemic: a qualitative study","volume":"16","author":"Galarneau","year":"2021","journal-title":"PLoS One"},{"key":"2023072815182081000_pgad064-B47","doi-asserted-by":"crossref","DOI":"10.15288\/jsad.21-00438","article-title":"COVID-19-related changes to drug-selling networks and their effects on people who use illicit opioids","author":"Frank","year":"2022","journal-title":"J Stud Alcohol Drugs"},{"key":"2023072815182081000_pgad064-B48","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.15585\/mmwr.mm7050e3","article-title":"Trends in and characteristics of drug overdose deaths involving illicitly manufactured fentanyls\u2014United States, 2019\u20132020","volume":"70","author":"O\u2019Donnell","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023072815182081000_pgad064-B49","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.15585\/mmwr.mm6935a1","article-title":"Vital signs: characteristics of drug overdose deaths involving opioids and stimulants\u201424 States and the District of Columbia, January\u2013June 2019","volume":"69","author":"O\u2019Donnell","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023072815182081000_pgad064-B50","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103127","article-title":"A rapid review of the impacts of \u201cBig Events \u201con risks, harms, and service delivery among people who use drugs: implications for responding to COVID-19","volume":"92","author":"Zolopa","year":"2021","journal-title":"Int J Drug Policy"},{"key":"2023072815182081000_pgad064-B51","article-title":"Centers for Disease Control and Prevention National Center for Injury Prevention and Control, Death Rate Maps & Graphs | Drug Overdose"},{"key":"2023072815182081000_pgad064-B52","author":"D. Enforcement Administration","year":"2020"},{"key":"2023072815182081000_pgad064-B53","author":"SAMHSA, National Survey on Drug Use and Health (NSDUH)"},{"key":"2023072815182081000_pgad064-B54","author":"Midgette"},{"key":"2023072815182081000_pgad064-B55","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.addbeh.2009.01.002","article-title":"Gender and comorbidity among individuals with opioid use disorders in the NESARC study","volume":"34","author":"Grella","year":"2009","journal-title":"Addict Behav."},{"key":"2023072815182081000_pgad064-B56","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/jamapsychiatry.2017.0113","article-title":"Changes in US lifetime heroin use and heroin use disorder","volume":"74","author":"Martins","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"2023072815182081000_pgad064-B57","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/archpsyc.64.5.566","article-title":"Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions","volume":"64","author":"Compton","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"2023072815182081000_pgad064-B58","author":"National Institute on Alcohol Abuse and Alcoholism"},{"key":"2023072815182081000_pgad064-B59","doi-asserted-by":"crossref","DOI":"10.1097\/ADM.0000000000001153","article-title":"Long-term effects of increasing buprenorphine treatment-seeking, duration, and capacity on opioid overdose fatalities: a model-based analysis","author":"Stringfellow","year":"2023","journal-title":"J Addict Med"},{"key":"2023072815182081000_pgad064-B60","author":"NFLIS","year":"2020"},{"key":"2023072815182081000_pgad064-B61","author":"United Nations Office on Drugs and Crime"},{"key":"2023072815182081000_pgad064-B62","author":"United Nations Office on Drugs and Crime"},{"key":"2023072815182081000_pgad064-B63","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1111\/add.12664","article-title":"The relationship between US heroin market dynamics and heroin-related overdose, 1992\u20132008","volume":"109","author":"Unick","year":"2014","journal-title":"Addiction"},{"key":"2023072815182081000_pgad064-B64","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/00952990.2020.1755677","article-title":"A dynamic model of the opioid drug epidemic with implications for policy","volume":"47","author":"Homer","year":"2021","journal-title":"Am J Drug Alcohol Abuse"},{"key":"2023072815182081000_pgad064-B65"},{"key":"2023072815182081000_pgad064-B66","doi-asserted-by":"crossref","DOI":"10.37573\/9781585284306","volume-title":"Demystifying opioid conversion calculations: a guide for effective dosing, 2nd edition","author":"McPherson","year":"2018"},{"key":"2023072815182081000_pgad064-B67"},{"key":"2023072815182081000_pgad064-B68","article-title":"Opioid equivalents and conversions","author":"Kishner","year":"2018","journal-title":"Medscape"},{"key":"2023072815182081000_pgad064-B69","author":"Substance Abuse and Mental Health Services Administration"},{"key":"2023072815182081000_pgad064-B70","author":"Substance Abuse and Mental Health Services Administration"},{"key":"2023072815182081000_pgad064-B71","article-title":"Harm reduction programs distribute one million doses of naloxone in 2019","author":"Wheeler","year":"2020","journal-title":"Medium"},{"key":"2023072815182081000_pgad064-B72","first-page":"631","article-title":"Opioid overdose prevention programs providing naloxone to laypersons\u2014United States, 2014","volume":"64","author":"Wheeler","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["PNAS Nexus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pnasnexus\/advance-article-pdf\/doi\/10.1093\/pnasnexus\/pgad064\/49418867\/pgad064.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pnasnexus\/article-pdf\/2\/4\/pgad064\/50997403\/pgad064.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pnasnexus\/article-pdf\/2\/4\/pgad064\/50997403\/pgad064.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T15:19:23Z","timestamp":1690557563000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pnasnexus\/article\/doi\/10.1093\/pnasnexus\/pgad064\/7069288"}},"subtitle":[],"editor":[{"given":"Bernice","family":"Pescosolido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,3,3]]},"references-count":72,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4,3]]}},"URL":"https:\/\/doi.org\/10.1093\/pnasnexus\/pgad064","relation":{},"ISSN":["2752-6542"],"issn-type":[{"value":"2752-6542","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,1]]},"published":{"date-parts":[[2023,3,3]]},"article-number":"pgad064"}}